Clinical Trials
6 trialsNCT03773302 2024-05-08
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
NCT04197986 2024-03-13
PROOF302
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT02150967 2023-07-03
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
QED Therapeutics, a BridgeBio company
Phase 2 Terminated
NCT01975701 2019-12-04
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
Novartis
Phase 2 Completed
NCT02160041 2019-06-18
CBGJ398XUS04
Novartis
Phase 2 Terminated